# Avista Pharma Solutions, Inc. – FDA Inspection, Aug 14, 2026

Source: https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc/5ddb9995-7883-41bf-b5d3-71b14a2b65d2
Source feed: FDA_Inspections

> FDA inspection 1332618 of Avista Pharma Solutions, Inc., August 14, 2026. 2 citations under 21 CFR part 211. Form 483 issued. 6 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1332618
- Company Name: Avista Pharma Solutions, Inc.
- Inspection Date: 2026-08-14
- Project Area: Human Cellular, Tissue, and Gene Therapies
- Product Type: Biologics
- Center: Biologics
- Office Name: New England District Office
- Citation Count: 2

## Related Documents

- [FDA Inspection 1278383 - 2025-07-25](https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc/07d264c9-9218-4fc2-92ce-25f1f2348432)
- [FDA Inspection 1113974 - 2019-12-18](https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc/43a50e53-b23a-4132-b1c6-e57509860e23)
- FDA Inspection 1067530 - 2018-09-05
- FDA Inspection 988732 - 2016-06-15
- [FDA Inspection 850250 - 2013-09-27](https://www.keypedia.com/records/fda_inspections/avista-pharma-solutions-inc/51fdbe29-4c8a-4db0-b664-5ef7edf67340)

Company: https://www.keypedia.com/companies/avista-pharma-solutions-inc/abe58c04-c144-4601-a4df-a290928bafa5

Office: https://www.keypedia.com/offices/new-england-district-office/aa458072-2f1d-4231-89f5-21ba7a3b7144